ent-gene-c90e6986 727 wordsTFEC Gene
<table class=“infobox infobox-gene”> <tr> <th class=“infobox-header” colspan=“2”>TFEC Gene</th> </tr> <tr> <td class=“label”>Gene Symbol</td> <td>TFEC</td> </tr> <tr> <td class=“label”>Full Name</td> <td>Transcription Factor EC</td> </tr> <tr> <td class=“label”>Chromosome</td> <td>6p21.1</td> </tr> <tr> <td class=“label”>Protein Family</td> <td>bHLH-Zip (MITF/TFEB/TFE3/TFEC)</td> </tr> <tr> <td class=“label”>Primary Expression</td> <td>Microglia, brain macrophages</td> </tr> <tr> <td class=“label”>Function</td> <td>Lysosomal biogenesis, autophagy regulation</td> </tr> <tr> <td class=“label”>Category</td> <td>Target Genes</td> </tr> <tr> <td class=“label”>Lysosomal function</td> <td>LAMP1, LAMP2, CTSD, GAA</td> </tr> <tr> <td class=“label”>Autophagy</td> <td>LC3, ATG14, BECN1, SQSTM1</td> </tr> <tr> <td class=“label”>Lipid metabolism</td> <td>PGC1α, PPARα</td> </tr> <tr> <td class=“label”>Immune response</td> <td>TREM2, CD68, CX3CR1</td> </tr> <tr> <td class=“label”>Feature</td> <td>TFEC</td> </tr> <tr> <td class=“label”>Primary cell type</td> <td>Microglia/macrophages</td> </tr> <tr> <td class=“label”>Brain expression</td> <td>High (microglia)</td> </tr> <tr> <td class=“label”>TREM2 crosstalk</td> <td>Direct</td> </tr> <tr> <td class=“label”>Therapeutic potential</td> <td>High</td> </tr> <tr> <td class=“label”>Approach</td> <td>Rationale</td> </tr> <tr> <td class=“label”>TFEC agonists</td> <td>Enhance lysosomal biogenesis in microglia</td> </tr> <tr> <td class=“label”>AAV-TFEC</td> <td>Gene therapy to boost autophagy</td> </tr> <tr> <td class=“label”>TREM2-TFEC axis</td> <td>Dual targeting</td> </tr> <tr> <td class=“label”>KG Connections</td> <td><a href=“/atlas” style=“color:#4fc3f7”>1 edges</a></td> </tr> </table>
Overview
Gene Structure and Function
TFEC (Transcription Factor EC) is a member of the MITF/TFEB/TFE3/TFEC family of basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factors. While TFEB and TFE3 are well-characterized master regulators of autophagy and lysosomal biogenesis, TFEC has distinct expression patterns and functions that make it particularly relevant to neurodegenerative disease research.
Structural Features
TFEC shares structural features with other family members:
- N-terminal transactivation domain: Regulates transcriptional activity
- bHLH-Zip DNA-binding domain: Binds to CLEAR (GTCACGTGAC) motif
- Proline-rich region: Mediates protein-protein interactions
- Leucine zipper domain: Facilitates dimerization with other bHLH-Zip proteins
Transcriptional Targets
TFEC regulates genes involved in:
Role in Cellular Processes
Lysosomal Biogenesis
TFEC, like its siblings TFEB and TFE3, drives expression of lysosomal and autophagic genes. The Ferreira et al. (2023) study demonstrated that TFEC is the predominant transcription factor controlling lysosomal biogenesis in microglia, with expression patterns distinct from TFEB. [@ferreira2023]
Autophagy Regulation
Through binding to CLEAR elements in target gene promoters, TFEC coordinates the autophagy-lysosome pathway:
flowchart TD
A["TFEC Activation<br/>mTOR inhibition, stress"] --> B["Nuclear Translocation"]
B --> C["CLEAR Motif Binding"]
C --> D["Target Gene Transcription"]
D --> E["Lysosomal Biogenesis"]
D --> F["Autophagy Induction"]
D --> G["Lipid Catabolism"]
H["TREM2 Signaling"] -->|"Crosstalk"| I["TFEC Activation"]
I --> B
Comparison with TFEB and TFE3
Relevance to Neurodegenerative Diseases
Alzheimer’s Disease
In AD, TFEC plays important roles through several mechanisms:
-
Microglial lysosomal function: TFEC maintains lysosomal capacity in disease-associated microglia (DAM), helping clear amyloid-beta and damaged organelles
-
TREM2 crosstalk: TFEC is directly regulated by TREM2 signaling in microglia. Loss of TREM2 function (protective variant R47H) impairs TFEC-mediated lysosomal biogenesis, contributing to reduced amyloid clearance
-
Autophagy impairment: In AD microglia, TFEC activity is reduced, leading to accumulation of autophagic vacuoles and impaired protein clearance
Parkinson’s Disease
TFEC involvement in PD relates to:
-
Alpha-synuclein clearance: TFEC-driven autophagy helps clear pathological α-synuclein aggregates
-
Microglial neuroinflammation: TFEC regulates anti-inflammatory programs in microglia
-
Lysosomal dysfunction: In PD with GBA mutations, TFEC activity may compensate for reduced lysosomal function
Therapeutic Potential
TFEC represents a promising therapeutic target:
Comparison with TFEB Therapy
While TFEB-activating drugs have been explored, TFEC offers advantages:
- Microglia-specific: TFEC is naturally enriched in microglia, reducing off-target effects
- TREM2 integration: Direct involvement in TREM2 signaling pathway
- Lower toxicity: TFEC activation may be safer than global TFEB activation
Cross-Linking
Related Genes
- TFEB — Master regulator of lysosomal biogenesis
- TFE3 — Related transcription factor
- MITF — Melanocyte master regulator
Related Proteins
Related Mechanisms
Disease Pages
References
: Ferreira J et al. TFEC controls lysosomal biogenesis in microglia. Nat Neurosci (2023) : Martina JA et al. The TFEB transcription factor regulates autophagy and lysosomal genes. Nat Cell Biol (2014) : Settembre C et al. TFEB links autophagy to cellular metabolism. Nature (2011) : Hsu CL et al. TFEB and TFE3 are involved in neurodegeneration. Autophagy (2018) : Palmieri M et al. TFEC is a macrophage-enriched transcription factor. J Exp Med (2021)
See Also
- TFEB Transcription Factor
- TFE3 Transcription Factor
- TREM2 Protein
- Microglial Activation Mechanisms
- Lysosomal Dysfunction in PD
- Autophagy Pathway
Related Hypotheses
From the SciDEX Exchange — scored by multi-agent debate
- APOE-Dependent Autophagy Restoration — <span style=“color:#81c784;font-weight:600”>0.73</span> · Target: MTOR
- Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators — <span style=“color:#81c784;font-weight:600”>0.63</span> · Target: CX3CR1
- Lysosomal Positioning Dynamics Modulation — <span style=“color:#ffd54f;font-weight:600”>0.56</span> · Target: LAMP1
- Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins — <span style=“color:#ffd54f;font-weight:600”>0.54</span> · Target: CX3CR1
- TFEB-PGC1α Mitochondrial-Lysosomal Decoupling — <span style=“color:#ffd54f;font-weight:600”>0.52</span> · Target: TFEB
- The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction — <span style=“color:#ffd54f;font-weight:600”>0.52</span> · Target: TFEB
- CYP46A1 Overexpression Gene Therapy — <span style=“color:#81c784;font-weight:600”>0.79</span> · Target: CYP46A1
- APOE-TREM2 Interaction Modulation — <span style=“color:#81c784;font-weight:600”>0.66</span> · Target: TREM2
Related Analyses: